Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time

Rhea-AI Summary

Caladrius Biosciences (Nasdaq: CLBS) will report its financial results for Q2 2021 on August 5, 2021, at 4:30 p.m. ET. The company focuses on developing cellular therapies to reverse diseases, including products like CLBS16, which has positive Phase 2a study results and a new Phase 2b study for treating coronary microvascular dysfunction. Other candidates include CLBS12 and CLBS201, with ongoing clinical trials. Investors can join the conference call via dial-in or webcast, with a replay available for 90 days.

Positive

• CLBS16 recently completed a positive Phase 2a study and has initiated a Phase 2b study.
• CLBS12 received orphan designation for Buerger’s Disease in the U.S., enhancing its market potential.
• OLOGO™ (CLBS14) has RMAT designation, indicating regulatory support for its clinical development.

Negative

• None.

BASKING RIDGE, N.J., July 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company will report its financial results for the three months ended June 30, 2021, on Thursday, August 5, 2021, at 4:30 p.m. (ET). To join the live conference call, please refer to the dial-in information provided below.

Dial-in information:
U.S. Toll-Free: 844-369-8774
International: 862-298-0844

A live webcast of the call will be available on the Caladrius website under the Investors & News section. A replay of the webcast will also be available for 90 days following the conclusion of the call.

For those unable to participate on the live conference call, an audio replay will be available that day starting at 7:30 p.m. (ET) until August 19, 2021, by dialing 877-481-4010 (U.S. Toll-Free) or 919-882-2331 (International) and by entering the replay passcode: 42180.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS12 (HONEDRA® in Japan), recipient of  orphan designation for Buerger’s Disease in the U.S. as well as  SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) and Buerger’s Disease based on the results of an ongoing clinical trial; CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (“DKD”); and OLOGO™ (CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company is in discussion with the FDA to finalize a Phase 3 protocol of reduced size and scope for a confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”).  For more information on the Company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@caladrius.com

Media:
Real Chemistry
Rachel Girard
Real Chemistry
Phone: 401-477-4030
Email: rgirard@realchemistry.com

FAQ

When will Caladrius Biosciences report its Q2 2021 financial results?

Caladrius Biosciences will report its Q2 2021 financial results on August 5, 2021.

What are the key products being developed by Caladrius Biosciences?

Caladrius is developing several products including CLBS16, CLBS12, CLBS201, and OLOGO™ (CLBS14).

How can I access the Caladrius financial results conference call?

Investors can join the conference call by dialing 844-369-8774 (U.S. Toll-Free) or 862-298-0844 (International).

What is the significance of the Phase 2 studies for Caladrius Biosciences?

The Phase 2 studies, particularly for CLBS16, provide critical data on efficacy and safety, impacting future development and potential market approval.